301258 Suzhou Fushilai Pharmaceutical
- 23.33
- -0.29-1.23%
Suzhou Fushilai Pharmaceutical News
Suzhou Fushilai Pharmaceutical: Announcement of Resolution of the Thirteenth Meeting of the Fourth Board of Supervisors.
Suzhou Fushilai Pharmaceutical: Orient Securities Co., Ltd.'s underwriting and sponsorship subsidiary has issued an opinion on the verification of Suzhou FULAI Pharmaceutical Co., Ltd.'s use of some idle funds for securities investment.
Suzhou Fushilai Pharmaceutical: Announcement of the resolutions of the 14th meeting of the 4th board of directors.
Suzhou Fushilai Pharmaceutical: Announcement on the Progress of Using Part of the Idle Raised Funds for Cash Management
Suzhou Fushilai Pharmaceutical: Notice of abnormal fluctuations in stock trading
Fujilai: Investor Relations Activity Record for April 24, 2024
Fujilai: Supervisory Board Resolutions Announcement
Fujilai: Special explanation on the use of non-operating capital and other related capital transactions in 2023
Fujilai: Verification Opinions of Orient Securities Underwriting and Sponsorship Co., Ltd. on the 2023 Internal Control Self-Assessment Report of Suzhou Fujilai Pharmaceutical Co., Ltd.
Fujilai: Report on the work of the Board of Directors for the year 2023
Fujilai: Oriental Securities Underwriting and Sponsorship Co., Ltd.'s inspection opinions on the storage and use of funds raised by Suzhou Fujilai Pharmaceutical Co., Ltd. in 2023
Fujilai: 2023 Independent Director's Debriefing Report (Kim Chun-kyung)
Fujilai: Orient Securities Underwriting and Sponsorship Co., Ltd. inspection opinions on the 2023 securities and derivatives investment situation of Suzhou Fujilai Pharmaceutical Co., Ltd.
Fujilai: Announcement on holding financial results briefings for the first quarter of 2023 and 2024
Fujilai: 2023 Report on the Work of the Supervisory Committee
Fujilai: 2023 Independent Director Debriefing Report (Tu Jiasheng) has left office
Fujilai: Orient Securities Underwriting and Sponsorship Co., Ltd. report on the 2023 continuous supervision and regular on-site inspection report of Suzhou Fujilai Pharmaceutical Co., Ltd.
Fujilai: Announcement on changes in accounting policies
Fujilai: Orient Securities Underwriting and Sponsorship Co., Ltd.'s 2023 Continuous Supervision and Follow-up Report on Suzhou Fujilai Pharmaceutical Co., Ltd.
Fujilai: Announcement on renewing the Company's 2024 Audit Institution
Analysis
Price Target
No Data
